Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 4(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01404923Phase 4Completed

Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)

Role: lead

NCT01840553Phase 3Completed

Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing

Role: lead

NCT01398098Phase 2Completed

Measurement of Gastric Emptying During and After COLOKIT® Intake

Role: lead

NCT00542295Phase 4Completed

Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

Role: lead

All 4 trials loaded